

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 March 2022 (17.03.2022)



(10) International Publication Number
WO 2022/053650 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 47/68* (2017.01)
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)
G01N 33/574 (2006.01) *A61K 39/00* (2006.01)
A61K 31/00 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/075005

(22) International Filing Date:

10 September 2021 (10.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/077,207 11 September 2020 (11.09.2020) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **KINNEER, Krista, Lynne**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **DAVIES, Gareth, Charles**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **REES, David, Gareth**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **PERCI-VAL-ALWYN, Jennifer, Louise**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **ANDREWS, John, Edward**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **CHESEBROUGH, Jon**; MedImmune, LLC One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

WO 2022/053650 A1

(54) Title: THERAPEUTIC B7-H4 BINDING MOLECULES

(57) Abstract: The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.